Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Long-Term Deferred Tax (2022 - 2025)

Sunshine Biopharma's Long-Term Deferred Tax history spans 4 years, with the latest figure at $92234.0 for Q3 2025.

  • For Q3 2025, Long-Term Deferred Tax changed N/A year-over-year to $92234.0; the TTM value through Sep 2025 reached $92234.0, changed N/A, while the annual FY2024 figure was $481747.0, 172.54% up from the prior year.
  • Long-Term Deferred Tax reached $92234.0 in Q3 2025 per SBFM's latest filing, roughly flat from $92234.0 in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $481747.0 in Q4 2024 to a low of $92234.0 in Q1 2025.
  • Average Long-Term Deferred Tax over 4 years is $206084.3, with a median of $134499.0 recorded in 2023.
  • Peak YoY movement for Long-Term Deferred Tax: tumbled 41.33% in 2023, then surged 172.54% in 2024.
  • A 4-year view of Long-Term Deferred Tax shows it stood at $301293.0 in 2022, then crashed by 41.33% to $176764.0 in 2023, then soared by 172.54% to $481747.0 in 2024, then crashed by 80.85% to $92234.0 in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Long-Term Deferred Tax are $92234.0 (Q3 2025), $92234.0 (Q2 2025), and $92234.0 (Q1 2025).